Found: 10
Select item for more details and to access through your institution.
Vaccinations in Paediatric Solid Organ Transplant Candidates and Recipients.
- Published in:
- Vaccines, 2024, v. 12, n. 9, p. 952, doi. 10.3390/vaccines12090952
- By:
- Publication type:
- Article
Long‐term endoscopic surveillance in HBV compensated cirrhotic patients treated with Tenofovir or Entecavir for 11 years.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2023, v. 57, n. 12, p. 1407, doi. 10.1111/apt.17463
- By:
- Publication type:
- Article
Incremental value of HBcrAg to classify 1582 HBeAg‐negative individuals in chronic infection without liver disease or hepatitis.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2021, v. 53, n. 6, p. 733, doi. 10.1111/apt.16258
- By:
- Publication type:
- Article
The combination of PIVKA‐II and AFP improves the detection accuracy for HCC in HBV caucasian cirrhotics on long‐term oral therapy.
- Published in:
- Liver International, 2020, v. 40, n. 8, p. 1987, doi. 10.1111/liv.14475
- By:
- Publication type:
- Article
Minimal increases of serum alpha‐foetoprotein herald HCC detection in Caucasian HBV cirrhotic patients under long‐term oral therapy.
- Published in:
- Liver International, 2019, v. 39, n. 10, p. 1964, doi. 10.1111/liv.14197
- By:
- Publication type:
- Article
Effectiveness and safety of switching to entecavir hepatitis B patients developing kidney dysfunction during tenofovir.
- Published in:
- Liver International, 2019, v. 39, n. 3, p. 484, doi. 10.1111/liv.14017
- By:
- Publication type:
- Article
<italic>IFNL4</italic> rs368234815 and rs117648444 variants predict off‐treatment HBsAg seroclearance in IFN‐treated HBeAg‐negative chronic hepatitis B patients.
- Published in:
- Liver International, 2018, v. 38, n. 3, p. 417, doi. 10.1111/liv.13526
- By:
- Publication type:
- Article
Treatment of hepatitis B: Is there still a role for interferon?
- Published in:
- Liver International, 2018, v. 38, p. 79, doi. 10.1111/liv.13635
- By:
- Publication type:
- Article
Hepatitis B virus long-term impact of antiviral therapy nucleot(s)ide analogues ( NUCs).
- Published in:
- Liver International, 2017, v. 37, p. 45, doi. 10.1111/liv.13291
- By:
- Publication type:
- Article
Circulating cell‐free DNA species affect the risk of hepatocellular carcinoma in treated chronic hepatitis B patients.
- Published in:
- Journal of Viral Hepatitis, 2021, v. 28, n. 3, p. 464, doi. 10.1111/jvh.13446
- By:
- Publication type:
- Article